​​​​​​​​​ ​​​​​​​​​​​​​​​​​​
otlogo.png
​​ ​​​

​​​Coverage from the 63rd ASH Annual Meeting & Exhibition

Focus on AML

​​ASH 2021: What to Know About This Year's Conference

The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition is back to meeting in person! This year, it will be held December 11-14, 2021, at the Georgia World Congress Center in Atlanta. 

A Retrospective Patient Analysis of Secondary AML & Prior HMA Exposure

​New research shows that patients with treated secondary acute myeloid leukemia (AML) and prior hypomethylating agent (HMA) exposure had significantly higher ORR rates and improved overall survival with HMA plus venetoclax when compared to intensive chemotherapy and low-intensity chemotherapy.  

Read More>

CPX-351 + Venetoclax in Newly Diagnosed or Relapsed/Refractory AML

For patients with acute myeloid leukemia (AML), one standard therapy has been the 7 + 3 regimen, which consists of 7 days of standard dosage cytarabine plus 3 days of an anthracycline derivative such as daunorubicin. 

​Read More >

Exploring Entospletinib Plus Decitabine in Certain Patients​

​Entospletinib in combination with decitabine showed activity among older, newly diagnosed acute myeloid leukemia (AML) patients with mutant TP53 or complex karyotype, but was associated with poor response and survival. 

Read More >

Leukemia & MDS Patients Recover From COVID-19 With Aggressive Treatment

Patients with acute leukemias or myelodysplastic syndromes (MDS) with active disease experience significantly higher COVID-19 severity, but not increased mortality from the infection. 

Read More >

Two COVID-19 Vaccine Doses Induce Strong Antibody Response in Myeloid Leukemias

Myeloid leukemia patients mount a strong antibody response after a second dose of the Moderna mRNA COVID-19 vaccine, according to the results of one of the largest studies to date of the antibody response to vaccination against COVID-19 in patients who had been treated for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 

Read More >

The Importance of Earlier End-of-Life Discussions in High-Risk AML

​​​Recent research suggests that discussions about end-of-life decisions occur too late in the illness course of patients with high-risk acute myeloid leukemia (AML), according to findings presented by study author Hannah R. Abrams, MD, of Massachusetts General Hospital, during the American Society of Hematology 2021 Annual Meeting & Exposition (Abstract 109).

​Read More >

Researcher Highlights Rare Genomic Event in Childhood Acute Myeloid Leukemia

​In a large cohort of patients with childhood acute myeloid leukemia (AML), who were treated with AAML1031, researchers identified a small subset with KMT2A partial tandem duplications (KMT2A-PTD) and a high prevalence of co-occurring FLT3 mutations, according to findings recently presented at the 2021 American Society of Hematology Annual Meeting & Exposition (Abstract 609).

​Read More>

Newly Diagnosed AML Patients Treated With Venetoclax-Based Regimens​

Recent findings from the ongoing AML Real World Evidence (ARC) Initiative sheds light on the real-world treatment and management of newly diagnosed acute myeloid leukemia (AML) patients treated with venetoclax-based regimens in academic sites, according to a presentation from the 2021 American Society of Hematology Annual Meeting & Exposition (Abstract 1271).

​Read More >

Finding a Biomarker for Better Response in IDH1- or IDH2-Mutated AML

Ivosidenib and enasidenib are inhibitors of mutant IDH1 and IDH2 in acute myeloid leukemia (AML), and are approved for the treatment of relapsed/refractory (R/R) AML with an IDH1 or IDH2 mutation. 

​Read More >

IDHentify Trial Findings of Late-Stage mIDH2 Relapsed/Refractory AML​

Data from the Phase III IDHentify trial supports the use of enasidenib as an oral outpatient treatment for patients with mutant IDH2 relapsed/refractory acute myeloid leukemia who are not candidates for intensive therapies, according to findings presented during the 2021 American Society of Hematology Annual Meeting & Exposition (Abstract 1243).

SWOG Model Results Predict Risk of Early Death in Patients With AML

An international team has developed statistical models to predict the risk of early death in patients being treated with non-intensive therapies for acute myeloid leukemia (AML). 

Read More >

Ivosidenib + Azacitidine in Newly Diagnosed AML Patients With IDH1 Mutation

Data from the Phase III AGILE study demonstrated that ivosidenib plus azacitidine significantly improved event-free survival, overall survival, and clinical response among patients with intensive chemotherapy-ineligible, newly diagnosed mutant IDH1 acute myeloid leukemia (AML) when compared to azacitidine alone. 

​Read More >

​​